YU38893A - Postupak za proizvodnju oslabljene varičela zoster virus vakcine - Google Patents
Postupak za proizvodnju oslabljene varičela zoster virus vakcineInfo
- Publication number
- YU38893A YU38893A YU38893A YU38893A YU38893A YU 38893 A YU38893 A YU 38893A YU 38893 A YU38893 A YU 38893A YU 38893 A YU38893 A YU 38893A YU 38893 A YU38893 A YU 38893A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- medium
- relaxed
- procedure
- manufacturing
- zoster virus
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/25—Varicella-zoster virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/36—Lipids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
POSTUPAK ZA PROIZVODNJU OSLABLJENE VARIČELA ZOSTER VIRUS VAKCINE, živa, oslabljena varičela zoster virus vakcina proizvodi se sa povećanim prinosom VZV. Novi postupak čini masovnu proizvodnju žive VZV vakcina praktičnijom. Pored toga, optimizirani uslovi monoslojne ćelijske kulture obezbedjuju postupak za maksimiziranje monoslojne ćelijske gustine, što je korisno za povećanje proizvodnje virusne vakcine. Prema ovom postupku, ćelijske gustine se približavaju 500,000 ćelija/cm2 i dobijaju se u konvencionalnim posudama kulture.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89403992A | 1992-06-04 | 1992-06-04 | |
US07/893,295 US5360736A (en) | 1992-06-04 | 1992-06-04 | Process for attenuated varicella zoster virus vaccine production |
Publications (2)
Publication Number | Publication Date |
---|---|
YU38893A true YU38893A (sh) | 1996-02-19 |
YU49210B YU49210B (sh) | 2004-09-03 |
Family
ID=27129046
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
YU38893A YU49210B (sh) | 1992-06-04 | 1993-06-02 | Postupak za proizvodnju oslabljene varičela zoster virus vakcine |
Country Status (28)
Country | Link |
---|---|
US (1) | US5607852A (sh) |
EP (2) | EP0573107B1 (sh) |
JP (2) | JP2599552B2 (sh) |
KR (1) | KR100350169B1 (sh) |
CN (2) | CN1069216C (sh) |
AT (2) | ATE206311T1 (sh) |
AU (2) | AU4392193A (sh) |
BG (1) | BG62176B1 (sh) |
CA (1) | CA2097019C (sh) |
CZ (2) | CZ289574B6 (sh) |
DE (2) | DE69334254D1 (sh) |
DK (2) | DK1097988T3 (sh) |
ES (2) | ES2317869T3 (sh) |
FI (1) | FI117758B (sh) |
GR (1) | GR3036812T3 (sh) |
HU (1) | HU220080B (sh) |
MX (1) | MX9303274A (sh) |
NO (1) | NO314068B1 (sh) |
NZ (1) | NZ253527A (sh) |
PT (2) | PT573107E (sh) |
RO (1) | RO114906B1 (sh) |
RS (1) | RS50330B (sh) |
RU (1) | RU2126269C1 (sh) |
SK (1) | SK279387B6 (sh) |
TW (1) | TW349868B (sh) |
UA (1) | UA27137C2 (sh) |
WO (1) | WO1993024616A1 (sh) |
YU (1) | YU49210B (sh) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995029991A1 (en) | 1994-04-28 | 1995-11-09 | Aviron | A novel vzv gene, mutant vzv and immunogenic compositions |
KR0177323B1 (ko) * | 1996-02-16 | 1999-04-01 | 성재갑 | 바이러스 백신 생산에 유용한 사람 이배체 폐세포 및 이를 이용한 수두 백신의 제조방법 |
ATE399855T1 (de) * | 1996-10-10 | 2008-07-15 | Invitrogen Corp | Tierzellkulturmedium mit pflanzlichen nährstoffen |
US20040171152A1 (en) * | 1996-10-10 | 2004-09-02 | Invitrogen Corporation | Animal cell culture media comprising non-animal or plant-derived nutrients |
GB9716611D0 (en) * | 1997-08-07 | 1997-10-08 | Cantab Pharmaceuticals Res Ltd | Virus preparations and methods |
US6210683B1 (en) | 1997-09-05 | 2001-04-03 | Merck & Co., Inc. | Stabilizers containing recombinant human serum albumin for live virus vaccines |
GB9804632D0 (en) | 1998-03-05 | 1998-04-29 | Cantab Pharma Res | Virus preparations and methods |
KR100378909B1 (ko) * | 1998-03-18 | 2003-12-18 | 주식회사 엘지생명과학 | 사람세포주를이용한풍진백신의생산수율증대방법 |
GB9808922D0 (en) * | 1998-04-24 | 1998-06-24 | Cantab Pharmaceuticals Res Ltd | Virus preparations |
WO1999057246A1 (en) * | 1998-05-01 | 1999-11-11 | Life Technologies, Inc. | Animal cell culture media comprising non-animal or plant-derived nutrients |
US20060286668A1 (en) * | 1999-04-30 | 2006-12-21 | Invitrogen Corporation | Animal-cell culture media comprising non-animal or plant-derived nutrients |
WO2001056600A1 (fr) * | 2000-01-31 | 2001-08-09 | The Research Foundation For Microbial Diseases Of Osaka University | Procede de controle des qualites d'un vaccin de poxvirus attenue |
CN1318580C (zh) * | 2003-07-10 | 2007-05-30 | 北京科兴生物制品有限公司 | 可满足灭活疫苗生产的sars病毒规模化制备及灭活的方法 |
US7344839B2 (en) * | 2004-12-23 | 2008-03-18 | Aurx, Inc. | Virus preparations and methods |
EP2069482A4 (en) * | 2006-10-17 | 2011-08-24 | Medimmune Llc | INFLUENCE OF VIRAL FAT COMPONENTS |
US20080294361A1 (en) * | 2007-05-24 | 2008-11-27 | Popp Shane M | Intelligent execution system for the monitoring and execution of vaccine manufacturing |
EP2310495B1 (en) * | 2008-08-11 | 2017-11-22 | Sanofi Pasteur Biologics, LLC | Compositions and methods for the production of alpha-herpesvirus 2 |
CN101967466A (zh) * | 2009-07-28 | 2011-02-09 | 新泽西医学院 | Orf7缺陷型水痘病毒株、含有该毒株的疫苗及其应用 |
FR2952825B1 (fr) | 2009-11-24 | 2012-05-25 | Goaster Jacqueline Le | Utilisation d'un vaccin contre le virus vzv/hsv3 pour traiter les infections herpetiques par le virus hsv1 et/ou le virus hsv2 |
CN101972474B (zh) * | 2010-11-11 | 2012-06-27 | 长春祈健生物制品有限公司 | 冻干带状疱疹减毒活疫苗及制备方法 |
EP2679683A4 (en) * | 2011-02-24 | 2015-07-15 | Mogam Biotech Res Inst | NEW STRAINS OF VARICELLA-ZOSTER VIRUS, VACCINE AGAINST VARICELLA AND HERPES-ZOSTER VIRUS USING THEM |
WO2014062060A1 (en) * | 2012-10-18 | 2014-04-24 | Erasmus University Medical Center Rotterdam | New method for producing high titer cell-free vzv vaccine virus |
CN103074304B (zh) * | 2013-01-28 | 2016-01-13 | 江苏健安生物科技有限公司 | 高水平人二倍体细胞培养水痘-带状疱疹疫苗病毒方法 |
US10350289B2 (en) | 2013-09-05 | 2019-07-16 | Merck Sharp & Dohme Corp. | Methods of immunization with varicella zoster virus antigen |
CN103740735B (zh) * | 2013-12-31 | 2016-04-06 | 李越希 | 化学合成的HSV2病毒gC糖蛋白胞外区基因片段及其表达、应用 |
MX2017007178A (es) * | 2014-12-01 | 2017-08-28 | Transgene Sa | Formulaciones liquidas estables de virus de vacuna. |
RU2637093C1 (ru) * | 2016-12-20 | 2017-11-29 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" (ФГБНУ НИИВС им. И.И. Мечникова) | Способ получения живой культуральной аттенуированной вакцины для профилактики ветряной оспы |
CN107174658B (zh) * | 2017-04-29 | 2020-11-27 | 安徽智飞龙科马生物制药有限公司 | 人用水痘病毒灭活疫苗及其制备方法 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3660565A (en) * | 1968-04-17 | 1972-05-02 | Wistar Inst | Rubella vaccine and method |
US3555149A (en) * | 1968-07-05 | 1971-01-12 | Merck & Co Inc | Mumps vaccine and its preparation |
US3919411A (en) * | 1972-01-31 | 1975-11-11 | Bayvet Corp | Injectable adjuvant and compositions including such adjuvant |
US3915794A (en) * | 1973-02-09 | 1975-10-28 | Rit Rech Ind Therapeut | Stabilizing compositions for cell-free viruses and cell-free virus preparations containing them |
JPS5341202B2 (sh) * | 1974-03-12 | 1978-11-01 | ||
US3961046A (en) * | 1974-12-02 | 1976-06-01 | American Cyanamid Company | Mumps vaccine and preparation thereof |
US4000256A (en) * | 1975-04-30 | 1976-12-28 | Merck & Co., Inc. | Varicella vaccine and process for its preparation |
GB1481650A (en) * | 1975-05-06 | 1977-08-03 | Merck & Co Inc | Chemical processes and products |
JPS5251009A (en) * | 1975-10-17 | 1977-04-23 | Morinaga Milk Ind Co Ltd | Method of producing drug for treating marrow leukemia |
US4147772A (en) * | 1976-02-03 | 1979-04-03 | Merck & Co., Inc. | Vaccine stabilizer |
JPS5341202A (en) * | 1976-09-28 | 1978-04-14 | Fuji Photo Film Co Ltd | Novel magnetic recording medium |
JPS55147227A (en) * | 1979-05-04 | 1980-11-17 | Handai Biseibutsubiyou Kenkyukai | Preparrtion of attenuated live mumps vaccine |
US4252792A (en) * | 1979-09-21 | 1981-02-24 | Douglas Industries, Inc. | Injectable rabies vaccine composition and method for preparing same |
US4273762A (en) * | 1979-12-03 | 1981-06-16 | Merck & Co., Inc. | Lyophilization process for live viral compositions |
US4337242A (en) * | 1980-02-05 | 1982-06-29 | Merck & Co., Inc. | Vaccine stabilizer containing L-glutamic acid and L-arginine |
US4338335A (en) * | 1980-02-05 | 1982-07-06 | Merck & Co., Inc. | Vaccine stabilizer containing L-glutamic acid and L-arginine |
US4772466A (en) * | 1983-08-22 | 1988-09-20 | Syntex (U.S.A.) Inc. | Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants |
JPS624370A (ja) * | 1985-07-01 | 1987-01-10 | Sharp Corp | 半導体素子 |
US5024836A (en) * | 1987-05-04 | 1991-06-18 | Merck & Co., Inc. | Stable lyophilized live herpes virus vaccine |
AU4312489A (en) * | 1988-09-23 | 1990-04-18 | Cetus Corporation | Lipid microemulsions for culture media |
US5360736A (en) * | 1992-06-04 | 1994-11-01 | Merck & Co., Inc. | Process for attenuated varicella zoster virus vaccine production |
-
1993
- 1993-05-26 WO PCT/US1993/004986 patent/WO1993024616A1/en active IP Right Grant
- 1993-05-26 SK SK1480-94A patent/SK279387B6/sk not_active IP Right Cessation
- 1993-05-26 RU RU94046296A patent/RU2126269C1/ru active
- 1993-05-26 CZ CZ19943045A patent/CZ289574B6/cs not_active IP Right Cessation
- 1993-05-26 AU AU43921/93A patent/AU4392193A/en not_active Abandoned
- 1993-05-26 US US08/347,345 patent/US5607852A/en not_active Expired - Lifetime
- 1993-05-26 UA UA94129122A patent/UA27137C2/uk unknown
- 1993-05-26 HU HU9403473A patent/HU220080B/hu unknown
- 1993-05-26 CA CA002097019A patent/CA2097019C/en not_active Expired - Lifetime
- 1993-05-26 NZ NZ253527A patent/NZ253527A/en not_active IP Right Cessation
- 1993-05-26 KR KR1019940704393A patent/KR100350169B1/ko not_active IP Right Cessation
- 1993-05-26 RO RO94-01924A patent/RO114906B1/ro unknown
- 1993-05-27 PT PT93201521T patent/PT573107E/pt unknown
- 1993-05-27 PT PT01200292T patent/PT1097988E/pt unknown
- 1993-05-27 AT AT93201521T patent/ATE206311T1/de active
- 1993-05-27 DK DK01200292T patent/DK1097988T3/da active
- 1993-05-27 EP EP93201521A patent/EP0573107B1/en not_active Expired - Lifetime
- 1993-05-27 ES ES01200292T patent/ES2317869T3/es not_active Expired - Lifetime
- 1993-05-27 DE DE69334254T patent/DE69334254D1/de not_active Expired - Lifetime
- 1993-05-27 AT AT01200292T patent/ATE419332T1/de active
- 1993-05-27 DE DE69330850T patent/DE69330850T2/de not_active Expired - Lifetime
- 1993-05-27 DK DK93201521T patent/DK0573107T3/da active
- 1993-05-27 TW TW082104197A patent/TW349868B/zh not_active IP Right Cessation
- 1993-05-27 EP EP01200292A patent/EP1097988B1/en not_active Expired - Lifetime
- 1993-05-27 ES ES93201521T patent/ES2161702T3/es not_active Expired - Lifetime
- 1993-06-01 MX MX9303274A patent/MX9303274A/es unknown
- 1993-06-02 YU YU38893A patent/YU49210B/sh unknown
- 1993-06-03 AU AU40036/93A patent/AU673167B2/en not_active Expired
- 1993-06-03 CN CN93106673A patent/CN1069216C/zh not_active Expired - Lifetime
- 1993-06-04 JP JP5134711A patent/JP2599552B2/ja not_active Expired - Lifetime
-
1994
- 1994-12-01 BG BG99227A patent/BG62176B1/bg unknown
- 1994-12-02 NO NO19944654A patent/NO314068B1/no not_active IP Right Cessation
- 1994-12-02 FI FI945697A patent/FI117758B/fi not_active IP Right Cessation
-
1996
- 1996-10-02 JP JP26218596A patent/JP3156962B2/ja not_active Expired - Lifetime
-
1998
- 1998-04-29 CZ CZ19981319A patent/CZ289690B6/cs not_active IP Right Cessation
-
2000
- 2000-10-05 CN CN00133104A patent/CN1307902A/zh active Granted
-
2001
- 2001-10-05 GR GR20010401425T patent/GR3036812T3/el unknown
-
2004
- 2004-01-26 RS YUP-75/04(62)P-388/93A patent/RS50330B/sr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
YU38893A (sh) | Postupak za proizvodnju oslabljene varičela zoster virus vakcine | |
ATE399855T1 (de) | Tierzellkulturmedium mit pflanzlichen nährstoffen | |
DE69637656D1 (de) | Methoden zur Züchtung von Tierzellen | |
NO922887D0 (no) | Fremgangsmaate for dannelse av cellemasse og/eller fermenteringsprodukter under sterile forhold samt anordning for utfoerelse av fremgangsmaaten | |
DE3681811D1 (de) | Verfahren zur kontinuierlichen herstellung von l-carnitin. | |
SE8500621D0 (sv) | Forbettrad proteinframstellning med anvendning av hypertoniska medier | |
EP0380692A4 (en) | Plant tissue culture process | |
US4169761A (en) | Process for the cultivation of viruses | |
Douglas | Uric acid utilization in Platymonas convolutae and symbiotic Convoluta roscoffensis | |
Tanabe | Visualization of the mitochondria of Toxoplasma gondii-infected mouse fibroblasts by the cationic permeant fluorescent dye rhodamine 123 | |
KR920012425A (ko) | 동물세포 배양용 고농도 배지 및 배양공정 | |
EP0987324A3 (en) | Cell growth accelerator containing polyphosphoric acid and cell growth method using the same | |
EP0276154A3 (en) | Method and apparatus for cell culture | |
EP0263659A3 (en) | Tissue culture media containing l-carnitine | |
JPS5668395A (en) | Production of d(-)-beta-hydroxyisobutyric acid | |
JPS5933353B2 (ja) | クロレラの培養法 | |
RU93048367A (ru) | Способ получения шиконина-5,8-дигидрокси-3-/1-гидрокси-4-метил-3-пентил/-1,4-нафтохинона | |
JPS5668394A (en) | Production of d(-)-beta-hydroxyisobutyric acid | |
RU2001123409A (ru) | Способ культивирования микроорганизмов Mycobacterium tuberculosis | |
SU1279236A1 (ru) | Способ непрерывного культивирования дрожжей | |
JPS6475096A (en) | Removal method for tetramethylammonium compound | |
RU93045458A (ru) | Способ культивирования галофильных бактерий |